Literature DB >> 32578169

Galectins in the Tumor Microenvironment: Focus on Galectin-1.

Neus Martínez-Bosch1, Pilar Navarro2,3.   

Abstract

In the last decades, the focus of cancer research has moved from epithelial cells to the tumor milieu, in an effort to better understand tumor development and progression, and with the important end goal of translating this knowledge into effective therapies. The galectin family of glycan-binding proteins displays important functions in cancer development and progression. Numerous groups have made outstanding contributions to deepen our knowledge about the role of galectins in the tumor-stroma crosstalk, defining them as key players in modulating interactions between tumor cells and the extracellular matrix, fibroblasts, endothelium, and the immune system. While several members of the family have been of particular interest until now, others are still considered as future exploding stars. This chapter provides an overview for galectin-1, the first identified and still one of the most well-studied galectins, and highlights the very important implications in its regulation of the tumor microenvironment in many different tumor types. Besides, a glimpse of the role of other galectins in the tumor milieu is also provided. Gaining a deeper understanding about the numerous roles of galectin-1 will not only help us to better understand other galectins but also is likely to result in the development of more effective cancer therapies.

Entities:  

Keywords:  Angiogenesis; Cancer therapy; Fibroblast activation; Galectin-1; Galectins; Immune evasion; Tumor microenvironment; Tumor-stroma crosstalk

Mesh:

Substances:

Year:  2020        PMID: 32578169     DOI: 10.1007/978-3-030-43093-1_2

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

Review 1.  Antibody-Drug Conjugates in Uro-Oncology.

Authors:  Dawid Sigorski; Paweł Różanowski; Ewa Iżycka-Świeszewska; Katarzyna Wiktorska
Journal:  Target Oncol       Date:  2022-05-14       Impact factor: 4.864

Review 2.  Galectin Family Members: Emerging Novel Targets for Lymphoma Therapy?

Authors:  Yuanwei Shi; Danting Tang; Xiaoqi Li; Xiaoli Xie; Yufu Ye; Lijuan Wang
Journal:  Front Oncol       Date:  2022-05-23       Impact factor: 5.738

Review 3.  Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure.

Authors:  Diego José Laderach; Daniel Compagno
Journal:  Cancers (Basel)       Date:  2021-09-09       Impact factor: 6.575

4.  Multi-Faceted Effects of ST6Gal1 Expression on Precursor B-Lineage Acute Lymphoblastic Leukemia.

Authors:  Mingfeng Zhang; Tong Qi; Lu Yang; Daniel Kolarich; Nora Heisterkamp
Journal:  Front Oncol       Date:  2022-03-16       Impact factor: 6.244

Review 5.  Recent advances in conventional and unconventional vesicular secretion pathways in the tumor microenvironment.

Authors:  I-Ying Kuo; Chih-Hsiung Hsieh; Wan-Ting Kuo; Chih-Peng Chang; Yi-Ching Wang
Journal:  J Biomed Sci       Date:  2022-08-05       Impact factor: 12.771

6.  Prevalence of serum galectin-1 autoantibodies in seven types of cancer: A potential biomarker.

Authors:  Tatsuki Nanami; Isamu Hoshino; Fumiaki Shiratori; Satoshi Yajima; Yoko Oshima; Takashi Suzuki; Masaaki Ito; Takaki Hiwasa; Akiko Kuwajima; Hideaki Shimada
Journal:  Mol Clin Oncol       Date:  2021-07-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.